Jennifer Doudna Sells 676 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Jennifer Doudna sold 676 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $75.55, for a total transaction of $51,071.80. Following the sale, the director owned 23,952 shares in the company, valued at $1,809,573.60. This represents a 2.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Tempus AI Price Performance

TEM traded up $0.94 during trading on Wednesday, hitting $74.91. 2,576,632 shares of the stock traded hands, compared to its average volume of 10,984,823. The business has a 50 day moving average price of $82.22 and a 200 day moving average price of $72.80. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. Tempus AI, Inc. has a twelve month low of $31.36 and a twelve month high of $104.32. The company has a market cap of $13.33 billion, a price-to-earnings ratio of -62.95 and a beta of 4.99.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company had revenue of $334.21 million for the quarter, compared to analyst estimates of $328.89 million. During the same quarter last year, the company posted ($0.46) EPS. The company’s revenue for the quarter was up 84.7% compared to the same quarter last year. Equities research analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TEM has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a report on Wednesday, October 8th. TD Cowen cut shares of Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 price objective for the company. in a research report on Tuesday, October 21st. Canaccord Genuity Group dropped their price objective on shares of Tempus AI from $110.00 to $95.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Cowen cut shares of Tempus AI from a “buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Finally, Morgan Stanley upped their price target on shares of Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $81.17.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently added to or reduced their stakes in the business. Cranbrook Wealth Management LLC bought a new stake in Tempus AI during the 3rd quarter worth approximately $25,000. Concord Wealth Partners lifted its holdings in shares of Tempus AI by 308.0% during the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock worth $26,000 after purchasing an additional 308 shares during the period. JPL Wealth Management LLC acquired a new position in shares of Tempus AI during the third quarter worth $26,000. GAMMA Investing LLC bought a new stake in shares of Tempus AI in the third quarter worth $28,000. Finally, Allworth Financial LP increased its holdings in Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the period. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.